JPWO2022016190A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022016190A5 JPWO2022016190A5 JP2023502897A JP2023502897A JPWO2022016190A5 JP WO2022016190 A5 JPWO2022016190 A5 JP WO2022016190A5 JP 2023502897 A JP2023502897 A JP 2023502897A JP 2023502897 A JP2023502897 A JP 2023502897A JP WO2022016190 A5 JPWO2022016190 A5 JP WO2022016190A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer cells
- seq
- fragment
- muc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 78
- 239000012634 fragment Substances 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 24
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 19
- 102100034256 Mucin-1 Human genes 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims description 4
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 102000009438 IgE Receptors Human genes 0.000 claims description 3
- 108010073816 IgE Receptors Proteins 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038111 Recurrent cancer Diseases 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 238000001794 hormone therapy Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010009992 CD163 antigen Proteins 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- -1 FcγRI (CD64) Proteins 0.000 claims description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 102100025136 Macrosialin Human genes 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 210000002445 nipple Anatomy 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 230000009131 signaling function Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052599P | 2020-07-16 | 2020-07-16 | |
| US63/052,599 | 2020-07-16 | ||
| PCT/US2021/070881 WO2022016190A1 (en) | 2020-07-16 | 2021-07-15 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534959A JP2023534959A (ja) | 2023-08-15 |
| JPWO2022016190A5 true JPWO2022016190A5 (enExample) | 2024-06-07 |
Family
ID=79554266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502897A Pending JP2023534959A (ja) | 2020-07-16 | 2021-07-15 | Ｍｕｃ１－ｃ／細胞外ドメイン（ｍｕｃ１－ｃ／ｅｃｄ）に対する抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230265208A1 (enExample) |
| EP (1) | EP4182354A4 (enExample) |
| JP (1) | JP2023534959A (enExample) |
| KR (1) | KR20230116767A (enExample) |
| CN (1) | CN117693530A (enExample) |
| AU (1) | AU2021310499A1 (enExample) |
| BR (1) | BR112023000728A2 (enExample) |
| CA (1) | CA3186181A1 (enExample) |
| IL (1) | IL299903A (enExample) |
| MX (1) | MX2023000784A (enExample) |
| WO (1) | WO2022016190A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202436357A (zh) * | 2023-03-03 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | Ｍｕｃ１抗體及使用方法 |
| TW202436343A (zh) * | 2023-03-03 | 2024-09-16 | 瑞士商百濟神州瑞士有限責任公司 | Muc1與cd16a抗體以及其使用方法 |
| WO2025217515A2 (en) | 2024-04-12 | 2025-10-16 | Dana-Farber Cancer Institute, Inc. | Identification of muc1-c as a target for the treatment of squamous cell carcinomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2601417C (en) * | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| CN106132992B (zh) * | 2014-01-29 | 2020-08-07 | 达娜-法勃肿瘤研究所公司 | 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体 |
| US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
-
2021
- 2021-07-15 US US18/005,562 patent/US20230265208A1/en active Pending
- 2021-07-15 AU AU2021310499A patent/AU2021310499A1/en active Pending
- 2021-07-15 BR BR112023000728A patent/BR112023000728A2/pt unknown
- 2021-07-15 WO PCT/US2021/070881 patent/WO2022016190A1/en not_active Ceased
- 2021-07-15 CA CA3186181A patent/CA3186181A1/en active Pending
- 2021-07-15 EP EP21842547.8A patent/EP4182354A4/en active Pending
- 2021-07-15 JP JP2023502897A patent/JP2023534959A/ja active Pending
- 2021-07-15 IL IL299903A patent/IL299903A/en unknown
- 2021-07-15 KR KR1020237005383A patent/KR20230116767A/ko active Pending
- 2021-07-15 MX MX2023000784A patent/MX2023000784A/es unknown
- 2021-07-15 CN CN202180063154.3A patent/CN117693530A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12215166B2 (en) | Bispecific antigen binding constructs targeting HER2 | |
| TWI830151B (zh) | 抗GPRC5DxBCMAxCD3三特異性抗體及其用途 | |
| JP6392923B2 (ja) | Ｍｕｃ１＊抗体 | |
| JP7438958B2 (ja) | 新規な抗体分子、その調製方法及びその使用 | |
| EP3237006B1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| US20250084184A1 (en) | Methods of using bispecific antigen-binding constructs targeting her2 | |
| CN112074534A (zh) | 双特异性抗原结合分子 | |
| EP3512886B1 (en) | Antigen binding protein against her3 | |
| JP2013500703A5 (enExample) | ||
| JP2019505545A5 (enExample) | ||
| CN120943966A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2022042719A5 (enExample) | ||
| JPWO2022016190A5 (enExample) | ||
| JPWO2021170068A5 (enExample) | ||
| WO2024235317A1 (zh) | 结合lilrb4和cd3的抗体及其用途 | |
| CN119505001B (zh) | 靶向cd22的全人源抗体及其应用 | |
| WO2024027828A1 (en) | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen | |
| JPWO2022251695A5 (enExample) | ||
| CN120271715A (zh) | 抗体及其药物偶联物和用途 | |
| JPWO2021170071A5 (enExample) | ||
| JPWO2023079102A5 (enExample) | ||
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела |